naltrexone has been researched along with guanfacine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gossop, M; Legarda, JJ | 1 |
| Intengan, HD; Smyth, DD | 1 |
| Pachler, M; Scahill, L | 1 |
| Blokhina, E; Burakov, A; Kosten, TR; Krupitsky, E; Masalov, D; Palatkin, V; Romanova, TN; Sinha, R; Tsoy, M; Tyurina, A; Verbitskaya, E; Wahlgren, V; Yaroslavtseva, T; Zvartau, E | 1 |
| Fredriksson, I; Jardemark, K; Jayaram-Lindström, N; Nylander, E; Nyström, E; Steensland, P; Wirf, M | 1 |
| Blokhina, EA; Burakov, AM; Bushara, EM; Grininko, AY; Kosten, T; Krupitsky, EM; Masalov, DV; Palatkin, VY; Romanova, TN; Sinha, R; Tiurina, AA; Verbitskaya, VE; Yaroslavtseva, TS; Zvartau, EE | 1 |
| McKee, SA; Ramchandani, VA; Roberts, W; Verplaetse, TL | 1 |
3 review(s) available for naltrexone and guanfacine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment of hyperactivity in children with pervasive developmental disorders.
Topics: Adrenergic alpha-Agonists; Amantadine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Child Psychiatry; Dopamine Agents; Guanfacine; Humans; Methylphenidate; Naltrexone; Narcotic Antagonists; Patient Selection; Treatment Outcome | 2007 |
A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers?
Topics: Adrenergic alpha-2 Receptor Agonists; Alcohol Deterrents; Alcohol-Related Disorders; Clinical Trials as Topic; Guanfacine; Humans; Naltrexone; Patient Selection | 2021 |
2 trial(s) available for naltrexone and guanfacine
| Article | Year |
|---|---|
Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Guanfacine; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Russia; Secondary Prevention; Young Adult | 2013 |
[A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Analgesics, Opioid; Double-Blind Method; Drug Therapy, Combination; Female; Guanfacine; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Secondary Prevention; Treatment Outcome; Young Adult | 2015 |
5 other study(ies) available for naltrexone and guanfacine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A 24-h inpatient detoxification treatment for heroin addicts: a preliminary investigation.
Topics: Administration, Oral; Adult; Conscious Sedation; Drug Administration Schedule; Follow-Up Studies; Guanfacine; Heroin Dependence; Humans; Intensive Care Units; Length of Stay; Male; Midazolam; Naltrexone; Neurologic Examination; Patient Admission; Premedication; Substance Abuse Detection; Substance Withdrawal Syndrome | 1994 |
Alpha-2a/d adrenoceptor subtype stimulation by guanfacine increases osmolar clearance.
Topics: Adrenergic alpha-Agonists; Animals; Body Water; Brimonidine Tartrate; Guanfacine; Idazoxan; Kidney; Male; Naltrexone; Prazosin; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2 | 1997 |
Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Central Nervous System Depressants; Choice Behavior; Conditioning, Operant; Disease Models, Animal; Drug Evaluation, Preclinical; Drug-Seeking Behavior; Ethanol; Glutamic Acid; Guanfacine; Male; Naltrexone; Prefrontal Cortex; Pyramidal Cells; Rats, Wistar; Tissue Culture Techniques; Treatment Outcome | 2015 |